FDA Places Partial Hold on Bright Minds’ BMB-101 Phase 2 Study for Epileptic Encephalopathies
Bright Minds says FDA partial hold on its BMB-101 DEE study is limited to the planned U.S. trial and does not affect other programs.
Bright Minds says FDA partial hold on its BMB-101 DEE study is limited to the planned U.S. trial and does not affect other programs.
Bright Minds Biosciences (DRUG) reports positive Phase 2 trial results for BMB-101, showing significant seizure reduction in patients with drug-resistant epilepsy.